Important change for UK divisional patent applications

ARTICLE SUMMARY

As from 1 May 2023 the UKIPO is changing its practice on the calculation of compliance periods for divisionals.

authors
No items found.
Related Services
Related Industries

As from 1 May 2023 the UKIPO is changing its practice on the calculation of compliance periods for divisionals.

This change is important because the compliance period for all divisional patent applications is the same absolute date as for the parent application. In all cases (both parent applications and divisional applications) the compliance period is set as either (i) four years six months from the earliest priority date (or the filing date if there is no priority); or (ii) 12 months from issue of the first substantive examination report on the parent application, if this expires later.

Under the IPO’s revised practice, all divisional applications will inherit the original and un-extended compliance period of the parent application. This means that even if the parent application has had the compliance period extended, the divisional will have the original, un-extended compliance period.

This has the effect that the latest that an applicant will be able to file a divisional application without relying on discretionary extensions of time is 1 month before the expiry of the un-extended compliance date of the parent application. Even if the compliance date on the parent is extended, any divisional application must still be filed at least 1 month before the expiry of the un-extended compliance date.

The latest that an applicant will be able to file a divisional application when relying on discretionary extensions of time is two months after the expiry of the un-extended compliance date of the parent application. Discretionary extensions of time to enable the filing of divisional applications will only generally be awarded if an applicant can show that the circumstances are exceptional and that they have been properly diligent.

If you may wish to file a divisional application based on a UK patent application or would like further information on how the change may effect you, please contact your Potter Clarkson attorney or email info@potterclarkson.com.

Related News

Priority patent applications for biotech and chemistry startups

Priority patent applications for biotech and chemistry startups

The deal killers investors often find too late: An IP lawyer’s guide to investor readiness

The deal killers investors often find too late: An IP lawyer’s guide to investor readiness

HPV-positive oropharyngeal cancer: prevention to precision treatment

HPV-positive oropharyngeal cancer: prevention to precision treatment

Unlocking the future of cleantech

Unlocking the future of cleantech

Winning at the EPO: Proven specialists in EPO oppositions

Winning at the EPO: Proven specialists in EPO oppositions

Protecting antibody innovations beyond composition claims

Protecting antibody innovations beyond composition claims

HPV vaccine success and the IP opportunities ahead

HPV vaccine success and the IP opportunities ahead

Fake weight-loss medications and new enforcement possibilities

Fake weight-loss medications and new enforcement possibilities

See All News
No items found.